IRIL Study (AMaRC 18-02)
A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma.
The purpose of this study is to determine whether Isatuximab (a new drug), when combined with chemotherapy, improves response to treatment.
Participating sites can enroll patient into study at the outset, which will then ensure patient can access Isatuximab upon failure to achieve CR at cycle 9.
For more information please visit
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Other (specify below)
Parts of research done:
Literature review, Research proposal, Ethics approval